Black Diamond Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Retrieved on:
Monday, November 8, 2021
Diamond, PK, FGFR, Lung cancer, Cancer, Private Securities Litigation Reform Act, Perk, Class, Clinical trial, R, Oncogene, Human, GBM, Vemurafenib, Investment, M26 Modular Accessory Shotgun System, Hyperphosphatemia, COVID-19, NEW, EGFR, Program, Annual report, Partnership, FGFR2, Conference, Company, Research, Black Diamond, Glioblastoma, Large-cell lung carcinoma, GLOBE, U.S. Securities and Exchange Commission, NSCLC, Drug discovery, BRAF, FGFR1, MAP, OpenEye Scientific Software, FGFR3, Nasdaq, Cell, Encorafenib, Patient, Dyckman Street station (IND Eighth Avenue Line), Pharmaceutical industry, Antibiotics, Trapping, Medical imaging, Lithium
and NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
Key Points:
- and NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
- Black Diamond remains on-track with preparations for initiating the Phase 2 portion of the MasterKey-01 Phase 1/2 study of BDTX-189 by the end of 2021.
- Black Diamond continues to advance BDTX-1535 through IND-enabling studies and expects to file an IND application by the first half of 2022.
- Black Diamond continues to progress its early-stage pipeline programs designed to target cancers driven by mutations in BRAF and FGFR.